GlassScriptPhysician profile
Yolana Fuks
NPI 1205220621
$272.78
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.73 · 2020: $195.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $44.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $44.40 | 2020 | |
| Dynavax Technologies Corporation | $42.98 | 2019-2020 | |
| Pfizer INC. | $41.50 | 2020 | |
| Phadia US INC. | $29.67 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $23.24 | 2020 | |
| Lilly USA, LLC | $20.00 | 2020 | |
| Hologic Sales and Service, LLC | $14.49 | 2019 | |
| Merck Sharp & Dohme LLC | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolana Fuks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.